Citadel Advisors
BCAB icon

Citadel Advisors’s BioAtla BCAB Stock Holding History

Citadel Advisors’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24
Closed -$416 – 12561
2025
Q1 		$416 Sell
24
-852
-97% -$18.2K ﹤0.01% 14266
2024
Q4 		$25.9K Buy
876
+206
+31% +$17.3K ﹤0.01% 13003
2024
Q3 		$59K Buy
670
+522
+353% +$43.8K ﹤0.01% 11730
2024
Q2 		$10.1K Buy
148
+56
+61% +$6.66K ﹤0.01% 13104
2024
Q1 		$15.8K Sell
92
-18
-16% -$2.24K ﹤0.01% 13163
2023
Q4 		$13.5K Buy
110
+28
+34% +$2.43K ﹤0.01% 12925
2023
Q3 		$6.97K Sell
82
-28
-25% -$3.57K ﹤0.01% 13286
2023
Q2 		$16.5K Sell
110
-86
-44% -$14.8K ﹤0.01% 12895
2023
Q1 		$26.3K Buy
196
+154
+367% +$27.7K ﹤0.01% 12850
2022
Q4 		$17.3K Sell
42
-498
-92% -$207K ﹤0.01% 13254
2022
Q3 		$208K Buy
540
+82
+18% +$26.8K ﹤0.01% 10326
2022
Q2 		$65K Buy
+458
New +$72.9K ﹤0.01% 11757

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors's BCAB Position: Q1 2026 in Review

Citadel Advisors opened a new position in BioAtla (BCAB) in Q1 2026: 8,714 shares worth $70.1K. The stake represents ﹤0.01% of the portfolio and ranks #12251 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in BCAB as recently as Q3 2025.

Citadel Advisors first reported a position in BCAB in Q4 2020 and has held it in 18 quarters since. The position peaked at $6.48M in Q2 2021. 36 funds tracked by Wall St. Rank hold BCAB as of Q1 2026.

  • Citadel Advisors held 8,714 shares of BioAtla worth $70.1K as of Q1 2026.
  • BioAtla was a new Citadel Advisors position in Q1 2026.
  • BioAtla made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12251 holding.
  • Citadel Advisors first reported a position in BioAtla in Q4 2020 and has held it in 18 quarters since.
  • Citadel Advisors's BioAtla position peaked at $6.48M in Q2 2021.
  • 36 funds tracked by Wall St. Rank held BioAtla as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.